Log In

Reset Password

First human trial in promising Beyond Cancer research

First Prev 1 2 3 Next Last
Ido Wolf, MD, head, oncology division, Tel Aviv Sourasky Medical Centre

Beyond Cancer Ltd, the exempted company registered in Bermuda that is focused on developing ultra-high concentration nitric oxide for the treatment of solid tumours, has announced that the first patient was treated in a first-in-human phase one study to assess the safety and immune biomarkers of UNO therapy.

Ido Wolf, MD, head, oncology division, Tel Aviv Sourasky Medical Centre; professor of oncology, faculty of medicine, Tel Aviv University; and head, National Israeli Council for Prevention, Diagnosis and Treatment of Malignant Diseases, said: “UNO therapy is very promising given the local delivery and surprising speed and ease of administration.

“I am looking forward to completing this phase one study and assessing the potential for efficacy.”

Selena Chaisson, CEO of Beyond Cancer, said: “We are proud to announce today the important milestone of advancing our UNO therapy into the clinic.

“This is a critical step in our mission to provide cancer patients a therapeutic option that may prevent metastases and end relapse. We anticipate initial clinical data from this trial in early 2023.”

Selena Chaisson, CEO of Beyond Cancer (File photograph)

Jedidiah Monson, MD, chief medical officer of Beyond Cancer, added: “This open-label, first-in-human, single administration, phase one study is a promising advancement as a new approach towards treating solid tumours with nitric oxide.

“The study will evaluate the maximum tolerated dose (MTD), safety and immune biomarkers of UNO injection into solid tumours that are not amenable to, or have failed, standard treatment.”

Jedidiah Monson, chief medical officer at Beyond Cancer Ltd (File photograph)

Steve Lisi, chairman and CEO of affiliate Beyond Air Inc and chairman of Beyond Cancer, said: "Once again the Beyond Air team executes, this time in collaboration with our Beyond Cancer colleagues. The team’s tireless efforts over the past three years have led us to this day.

“We will continue our rapid development to determine what role UNO therapy may play in the fight against solid tumours.”

The company said the primary endpoints of the phase one study are the incidence and characteristics of adverse events, serious adverse events, dose-limiting toxicities and changes in safety parameters.

It said the dose for future studies will be determined based on the MTD with additional consideration for all available safety and biomarker data.

The company added that the secondary endpoints include standard efficacy measures of stable disease, partial response, complete response, overall response rate or confirmed disease progression status at the treatment site, as well as survival.

You must be Registered or to post comment or to vote.

Published August 24, 2022 at 7:42 am (Updated August 24, 2022 at 8:09 am)

First human trial in promising Beyond Cancer research

What you
Need to
1. For a smooth experience with our commenting system we recommend that you use Internet Explorer 10 or higher, Firefox or Chrome Browsers. Additionally please clear both your browser's cache and cookies - How do I clear my cache and cookies?
2. Please respect the use of this community forum and its users.
3. Any poster that insults, threatens or verbally abuses another member, uses defamatory language, or deliberately disrupts discussions will be banned.
4. Users who violate the Terms of Service or any commenting rules will be banned.
5. Please stay on topic. "Trolling" to incite emotional responses and disrupt conversations will be deleted.
6. To understand further what is and isn't allowed and the actions we may take, please read our Terms of Service
7. To report breaches of the Terms of Service use the flag icon